Fig. 4: Qβ-PHF1 vaccination preferentially reduces Sarkosyl insoluble tau in rTg4510 mice and elicits antibodies specific to human pathological tau.
From: pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy model
a Western blot of Sarkosyl soluble and insoluble tau from Qβ-PHF1 and Qβ Control vaccinated mouse hippocampal samples b showing a significant reduction in the ratio of Sarkosyl insoluble/soluble AT8+ and Tau12+ tau in Qβ-PHF1 vaccinated mice compared to Qβ Control. c, d Gallyas silver impregnation of the cortex and CA1 hippocampal sections from Qβ-PHF1 and Qβ Control vaccinated mice showed a significant reduction in insoluble tau and dramatic clearance of NFTs of Qβ-PHF1 vaccinated mice compared to the Qβ Control group. e Qβ-PHF1 immune sera stained somatodendritic NFTs, pre-tangles, neuritic plaques, neuropil threads, and ghost tangles in human autopsy AD, but not non-AD, brain tissue. Qβ Control sera did not show any specific staining. AT8 antibody staining was used as a positive control. All graphs show mean ± SEM. Student’s t-test (b, d). p < 0.05*, p < 0.01**. b Qβ Control (n = 5), Qβ-PHF1 (n = 8). d Qβ Control (n = 5), Qβ-PHF1 (n = 5).
